Trial Profile

A Controlled Study to Evaluate the Safety and Efficacy of Allogeneic MesenCure for the Treatment of Pulmonary Manifestations in Patients With COVID19

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Feb 2025 According to a Bonus BioGroup media release, company announced that it has received U.S. Food and Drug Administration (FDA) clearance to proceed with a Phase III clinical study in the United States to evaluate the efficacy and safety of MesenCure to treat respiratory distress in hospitalized, severely ill patients resulting from pneumonia related to COVID-19. The IND application is supported, among other factors, by results from a Phase II clinical study of MesenCure completed in 2022.
25 Aug 2021 New trial record
22 Aug 2021 According to a Bonus BioGroup media release, the company has received approval from the Israeli Ministry of Health to expand this trial to medical centers across Israel.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com